Nabumetone

Summary

Nabumetone (CHEMBL1070) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AX01); indicated across 3 conditions including rheumatic disorder and rheumatoid arthritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AX01
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 228.29 Da · C15H16O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1070
Name	Nabumetone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4409
ChEBI	CHEBI:7443
ATC	M01AX01
Molecular formula	C15H16O2
Molecular weight	228.29
InChIKey	BLXXJMDCKKHMKV-UHFFFAOYSA-N

SMILES: CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC

IUPAC name: 4-(6-methoxynaphthalen-2-yl)butan-2-one

ChEBI definition: A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, cyclooxygenase 2 inhibitor, prodrug.

Also known as: BRL 14777, BRL-14777, Nabumetona, Nabumetone, NSC-758623, Relafen, Relifex, SID11112767, SID26748824, SID8139968, NABUMETONE, nabumetone

Patent coverage: 13,721 distinct patent families (55,063 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 54,696 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Amine oxidase [flavin-containing] A, Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 22 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP1A2	6.4	AC50	398.1	nM	CHEMBL_ACT_6003670
LMNA	6.25	Potency	562.3	nM	CHEMBL_ACT_3660986
MAOA	6	IC50	998	nM	CHEMBL_ACT_7767246
SLC6A2	5.73	IC50	1868	nM	CHEMBL_ACT_7765135
SLC6A2	5.73	Ki	1853	nM	CHEMBL_ACT_7765136
RAB9A	5.55	Potency	2818	nM	CHEMBL_ACT_3850488
NPC1	5.55	Potency	2818	nM	CHEMBL_ACT_4752964
CYP1A2	5.3	IC50	5000	nM	CHEMBL_ACT_7767172
KDM4E	5.15	Potency	7080	nM	CHEMBL_ACT_3722012
SLC6A3	5.11	AC50	7800	nM	CHEMBL_ACT_25123991

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
osteoarthritis	4	MONDO:0005178	MONDO:0005178

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01164813	PHASE1	COMPLETED	Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy’s Under Fasting Conditions
NCT01164826	PHASE1	COMPLETED	Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy’s Under Fed Conditions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dip	CPIC	CYP2C9

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).